Home LiteratureArticle Details
PMID: 26640402 Published · epublish English

Role and New Insights of Pirfenidone in Fibrotic Diseases.

International journal of medical sciences ·Vol. 12 ·No. 11 ·2016-09-27

Lopez-de la Mora David Alejandro, Sanchez-Roque Cibeles, Montoya-Buelna Margarita, Sanchez-Enriquez Sergio, Lucano-Landeros Silvia, Macias-Barragan Jose, Armendariz-Borunda Juan

Abstract

Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression, which is highly related to prevent or remove excessive deposition of scar tissue in several organs. Basic and clinical evidence suggests that PFD may safely slow or inhibit the progressive fibrosis swelling after tissue injuries. Furthermore, a number of evidence suggests that this molecule will have positive effects in the treatment of other inflammatory diseases. This review contains current research in which PFD has been used as the treatment of several diseases, and focus mainly in the outcomes related to improve inflammation and fibrogenesis. Therefore, the main goal of this review is to focus on the novel findings of PFD efficacy rather than deepen in the chemical aspects of the molecule.

Keywords
Pirfenidone fibrosis idiopathic pulmonary fibrosis inflammation
Article Info
Journal
International journal of medical sciences
Abbr.
Int J Med Sci
Published
2016-09-27
Indexed
2015-12-07
Updated
2016-12-06
Language
English
Country/Region
Australia
NLM ID
101213954
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]